Secondary malignancy after urologic reconstruction procedures: a multi-institutional case series.
Chelsea Cornell1, Francesca Khani2, Adeboye O Osunkoya3
1Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Human Pathology
|November 21, 2021
Summary
Secondary malignancies after urologic reconstruction are rare but aggressive. Most cases are adenocarcinomas presenting late, requiring multimodality treatment for these complex urinary diversion tumors.
Area of Science:
- Urologic oncology
- Surgical pathology
- Medical reconstruction
Background:
- Urinary diversion and reconstructive urologic procedures often use intestinal segments.
- Malignancy risk is known after these procedures, but tumor characteristics are poorly understood.
Purpose of the Study:
- To evaluate clinicopathological features of secondary tumors after urologic reconstruction.
- To analyze histopathologic and immunohistochemical profiles of these rare malignancies.
Main Methods:
- Retrospective review of 11 cases from 5 institutions.
- Analysis of surgical history, tumor morphology, and immunohistochemical markers (CK7, CK20, CK903, CDX2, SATB2, beta-catenin, GATA-3).
- Evaluation of pathologic stage, metastasis, treatment, and patient outcomes.
Main Results:
- Median age 51.7 years; 8:3 M:F ratio.
- Most common reconstructions: ileal conduits (7), gastrocystoplasties (2).
- Median time to malignancy: 36 years.
- Adenocarcinoma (10/11) was the most frequent histology, with specific immunohistochemical profiles (e.g., CK20+, CDX2+, beta-catenin+).
- High rates of advanced stage (T3-T4: 30%) and lymph node metastasis (60%).
Conclusions:
- Secondary malignancy after urologic reconstruction is rare, typically adenocarcinoma.
- These tumors present late, exhibit aggressive behavior, and often require multimodality therapy.
- Further research into risk factors and treatment strategies for these unique oncologic entities is warranted.
